All In Biotech

NDA 050742 · Merck Sharp Dohme

Stromectol

Ivermectin · Oral · Antiparasitic; Pediculicide

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Mar 14, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Nov 22, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

221

83 Phase 3, 9 recruiting

FAERS reports

4,851

3,461 serious, 563 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 20, 2024.

INDICATIONS AND USAGE STROMECTOL is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract . STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies .) Onchocerciasis . STROMECTOL is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: STROMECTOL has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 22, 1996 Original approval · Type 1 - New Molecular Entity · priority review Review
2 products under this application
  • STROMECTOL · IVERMECTIN 3MG · TABLET, ORAL · Discontinued · TE AB
  • STROMECTOL · IVERMECTIN 6MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Ivermectin" as an intervention, any sponsor and status, largest first.

All 221 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache611
  • asthenia582
  • pyrexia474
  • off label use463
  • drug ineffective450
  • product use in unapproved indication415
  • diarrhoea267
  • ocular hyperaemia248
  • coma247
  • conjunctival haemorrhage237
  • back pain224
  • vertigo215

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200495
200563
2006360
200796
2008186
200984
2010139
201153
201272
201392
2014107
2015110
201689
2017110
2018195
2019190
2020216
2021467
2022426
2023350
2024361
2025555
2026435

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Sep 29, 2026

    STROMECTOL, Tablet, 3 mg (NDC 0006-0032-01). Product will be discontinued on 10/31/2026

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Stromectol (IVermectin)

2024 spending

$995

Beneficiaries

14

19 claims

Per beneficiary

$71

$4.55 per unit

View as table
YearSpending
2020$5,243
2021$34,111
2022$4,324
2023$1,634
2024$995

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 833 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.